deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01738139

Ipilimumab and Imatinib Mesylate in Advanced Cancer

A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced Malignancies

Sponsor: M.D. Anderson Cancer Center

Conditions Advanced Malignant Solid Neoplasm C-KIT Tyrosine Kinase Protein Overexpression Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Gastrointestinal Stromal Tumor Metastatic Malignant Solid Neoplasm Metastatic Melanoma Pathologic Stage IV Cutaneous Melanoma AJCC v8 Unresectable Melanoma Unresectable Solid Neoplasm
Interventions Imatinib Mesylate Ipilimumab
Updated 15 times since 2017 Last updated: Mar 20, 2024 Started: Feb 19, 2013 Primary completion: Dec 13, 2022 Completion: Dec 13, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01738139, this PHASE1 trial focuses on Advanced Malignant Solid Neoplasm and C-KIT Tyrosine Kinase Protein Overexpression and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 15 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jun 2019 · 8 months · monthly snapshot~Jun 2019 – ~Apr 2020 · 10 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Oct 2023 · 7 months · monthly snapshot~Oct 2023 – ~Apr 2024 · 6 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Oct 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Mar 2023 — Oct 2023 [monthly]

    Recruiting PHASE1

▶ Show 10 earlier versions

  1. Sep 2022 — Mar 2023 [monthly]

    Recruiting PHASE1

  2. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE1

  3. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  4. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  5. Jun 2019 — Apr 2020 [monthly]

    Recruiting PHASE1

  6. Oct 2018 — Jun 2019 [monthly]

    Recruiting PHASE1

  7. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  8. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  9. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE1

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations